These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 2400985)

  • 1. Effect of heat treatment on tumor cells and antitumor effector cells.
    Mise K; Kan N; Okino T; Nakanishi M; Satoh K; Teramura Y; Yamasaki S; Ohgaki K; Tobe T
    Cancer Res; 1990 Oct; 50(19):6199-202. PubMed ID: 2400985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of combined immunotherapy using two different BRMs; OK-432 and IL-2-cultured lymphocytes].
    Kan N; Hori T; Ohgaki K; Inamoto T; Kodama H; Tobe T
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1298-306. PubMed ID: 3488027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
    Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
    J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. II. Enhancement of in vitro cell-mediated cytotoxicity by combined chemotherapy-immunotherapy.
    Adler A; Keisari Y; Ofir R
    J Natl Cancer Inst; 1985 Feb; 74(2):429-36. PubMed ID: 3856051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new model of active specific immunotherapy using interleukin-1 and sonicated tumor supernatant in murine tumor system.
    Moriguchi Y; Kan N; Okino T; Harada T; Yamasaki S; Ichinose Y; Li L; Sugie T; Imamura M
    J Surg Oncol; 1996 Jun; 62(2):78-85. PubMed ID: 8649045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells.
    Suzuki T; Fukuhara T; Tanaka M; Nakamura A; Akiyama K; Sakakibara T; Koinuma D; Kikuchi T; Tazawa R; Maemondo M; Hagiwara K; Saijo Y; Nukiwa T
    Clin Cancer Res; 2005 Jan; 11(1):58-66. PubMed ID: 15671528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
    Adler A; Altbaum I
    J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells.
    Shu S; Rosenberg SA
    J Immunol; 1985 Oct; 135(4):2895-903. PubMed ID: 2411817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma.
    Morecki S; Yacovlev E; Gelfand Y; Uzi I; Slavin S
    J Immunother; 2001; 24(2):114-21. PubMed ID: 11265768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors.
    Mokyr MB; Hengst JC; Dray S
    Cancer Res; 1982 Mar; 42(3):974-9. PubMed ID: 6977410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cationic lipid:bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models.
    Lanuti M; Rudginsky S; Force SD; Lambright ES; Siders WM; Chang MY; Amin KM; Kaiser LR; Scheule RK; Albelda SM
    Cancer Res; 2000 Jun; 60(11):2955-63. PubMed ID: 10850443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
    Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinational FLt3 ligand and granulocyte macrophage colony-stimulating factor treatment promotes enhanced tumor infiltration by dendritic cells and antitumor CD8(+) T-cell cross-priming but is ineffective as a therapy.
    Berhanu A; Huang J; Alber SM; Watkins SC; Storkus WJ
    Cancer Res; 2006 May; 66(9):4895-903. PubMed ID: 16651446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent delivery of GM-CSF and endostatin genes by a single adenoviral vector provides a synergistic effect on the treatment of orthotopic liver tumors.
    Tai KF; Chen PJ; Chen DS; Hwang LH
    J Gene Med; 2003 May; 5(5):386-98. PubMed ID: 12731087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoreactive and heat shock protein 60-recognizing CD4+ T-cells show antitumor activity against syngeneic fibrosarcoma.
    Harada M; Matsuzaki G; Yoshikai Y; Kobayashi N; Kurosawa S; Takimoto H; Nomoto K
    Cancer Res; 1993 Jan; 53(1):106-11. PubMed ID: 8093229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Photodynamic therapy-mediated immune response against subcutaneous mouse tumors.
    Korbelik M; Dougherty GJ
    Cancer Res; 1999 Apr; 59(8):1941-6. PubMed ID: 10213504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing the factors which modify thermal enhancement of melphalan in a spontaneous murine tumor.
    Mohamed F; Stuart OA; Glehen O; Urano M; Sugarbaker PH
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):719-24. PubMed ID: 16614851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
    Fuyama S; Yamamoto H; Fujii Y; Arai S
    Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effector mechanism of tumor immunity in murine plasmacytoma.
    Chen YH; Anderson AB
    Cancer Res; 1988 Mar; 48(6):1398-403. PubMed ID: 3257896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysis of antigenically unrelated tumor cells mediated by Lyt 2+ splenic T-cells from melphalan-cured MOPC-315 tumor bearers.
    Barker E; Wise JA; Dray S; Mokyr MB
    Cancer Res; 1989 Sep; 49(18):5007-15. PubMed ID: 2788494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.